Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.62 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 6/20 | 0.58 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.51 |
| ▸ | IGF1R | P08069 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | BCR | P11274 | 1/20 | 0.51 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25603960 | 0.91 | EHMT2 (0.62) | EHMT2EHMT1SRCCDK1KDR | |
| SCHEMBL19477263 | 0.86 | EHMT2 (0.65) | EHMT2EHMT1LRRK2IGF1REGFR | |
| SCHEMBL19700624 | 0.86 | EHMT2 (0.65) | EHMT2EHMT1KDRLRRK2IGF1R | |
| SCHEMBL19476358 | 0.84 | EHMT2 (0.62) | EHMT2EHMT1LRRK2IGF1R | |
| SCHEMBL25610814 | 0.83 | EHMT2 (0.61) | EHMT2EHMT1LRRK2IGF1REGFR | |
| SCHEMBL19476661 | 0.81 | EHMT2 (0.66) | EHMT2EHMT1SRCIGF1REGFR | |
| SCHEMBL30367655 | 0.81 | EHMT2 (0.66) | EHMT2EHMT1SRCIGF1REGFR | |
| SCHEMBL19477279 | 0.81 | EHMT2 (0.77) | EHMT2EHMT1SRCCDK1KDR | |
| SCHEMBL19477067 | 0.80 | EHMT2 (0.64) | EHMT2EHMT1SRCIGF1REGFR | |
| SCHEMBL19476359 | 0.80 | EHMT2 (0.69) | EHMT2EHMT1SRCKDRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3442947-B1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | EPIZYME INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| WO-2017181177-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | EHMT2 1/4885EHMT1 6/4885SRC 1788/4885 |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | EHMT2 4/4885EHMT1 7/4885SRC 1984/4885 |
| US-20210198277-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | EHMT2 4/4885EHMT1 7/4885SRC 1984/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | EHMT2 1/4885EHMT1 6/4885SRC 1788/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | EHMT2 1/4885EHMT1 2/4885SRC 3954/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | EHMT2 1/4885EHMT1 6/4885SRC 1788/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | EHMT2 1/4885EHMT1 4/4885SRC 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.